Items covered in this weekend news report include:
- Acrylamide exposure as a potential risk for prostate cancer
- The relative merits of three standard first-line therapies in intermediate risk prostate cancer
- Estramustine + etopside in hormone-refractory prostate cancer (HRPC)
- Bone turnover markers and risk for skeletal-related events in patients receiving zoledronic acid … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: acrylamide, bone turnover markers, brachytherapy, carcinogen, estramustine, etopside, external beam radiation, HRPC, risk, skeletal-related events, SREs, surgery | Leave a comment »
